Peptides in oral diseases

Current Pharmaceutical Design

Volumn 18, Issue 6, 2012, Pages 782-788

  Lucchese, Alberta ^a   Guida, Agostino ^a   Petruzzi, Massimo ^b   Capone, Giovanni ^b   Laino, Luigi ^a   Serpico, Rosario ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Antimicrobial peptides; Bacterial competence stimulating peptides; Cytokeratin peptides; Desmoglein 3 peptide; Oral infectious diseases; Oral squamous cell carcinomas; Pemphigus vulgaris

Indexed keywords

ADRENOMEDULLIN; BETA DEFENSIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DESMOGLEIN 3; HISTATIN; POLYPEPTIDE ANTIBIOTIC AGENT;

ARTICLE; GENE EXPRESSION; HEALTH; HUMAN; MOUTH CAVITY; MOUTH DISEASE; MOUTH INFECTION; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

AMINO ACID SEQUENCE; BACTERIAL INFECTIONS; GENE EXPRESSION REGULATION; HUMANS; MOUTH DISEASES; PEPTIDES;

EID: 84856458477     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799277842     Document Type: Article

References (129)

1. Takahashi N, Nyvad B. The role of bacteria in the caries process: ecological perspectives. J Dent Res 2011; 90: 294-303.
2. Russell RR. Changing concepts in caries microbiology. Am J Dent 2009; 22: 304-10.
3. Heuer W, Kettenring A, Stumpp SN, et al. Metagenomic analysis of the peri-implant and periodontal microflora in patients with clinical signs of gingivitis or mucositis. Clin Oral Investig Forthcoming 2011; doi 10.1007/s00784-011-0561-8.
4. Uzel NG, Teles FR, Teles RP, et al. Microbial shifts during dental biofilm re-development in the absence of oral hygiene in periodontal health and disease. J Clin Periodontol 2011; 38: 612-20.
5. Kebschull M, Papapanou PN. Periodontal microbial complexes associated with specific cell and tissue responses. J Clin Periodontol 2011; 38: 17-27.
6. Signat B, Roques C, Poulet P, Duffaut D. Fusobacterium nucleatum in periodontal health and disease. Curr Issues Mol Biol 2011; 13: 25-36.
7. Groeger S, Doman E, Chakraborty T, Meyle J. Effects of Porphyromonas gingivalis infection on human gingival epithelial barrier function in vitro. Eur J Oral Sci 2010; 118: 582-9.
8. Roberts AP, Mullany P. Oral biofilms: a reservoir of transferable, bacterial, antimicrobial resistance. Expert Rev Anti Infect Ther 2010; 8: 1441-50.
9. Cannon RD, Chaffin WL. Oral colonization by Candida albicans. Crit Rev Oral Biol Med 1999; 10: 359-83.
10. Williams DW, Lewis MA. Isolation and identification of Candida from the oral cavity. Oral Dis 2000; 6: 3-11.
11. Zheng Y, Xia P, Zheng HC, Takahashi H, Masuda S, Takano Y. The screening of viral risk factors in tongue and pharyngolaryngeal squamous carcinoma. Anticancer Res 2010; 30: 1233-8.
12. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11: 781-9.
13. Lee SY, Cho NH, Choi EC, et al. Relevance of human papilloma virus (HPV) infection to carcinogenesis of oral tongue cancer. Int J Oral Maxillofac Surg 2010; 39: 678-83.
14. Meurman JH. Infectious and dietary risk factors of oral cancer. Oral Oncol 2010; 46: 411-13.
15. Bakri MM, Hussaini MH, Holmes RA, Cannon DR, Rich MA. Revisiting the association between candidal infection and carcinoma, particularly oral squamous cell carcinoma. J Oral Microbiol 2010; 21: 2.
16. Lodi G, Porter SR. Hepatitis C virus infection and lichen planus: a short review. Oral Dis 1997; 3: 77-81.
17. Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Int Rev Immunol 1997; 14: 21-32.
18. Levi ME, Eusterman VD. Oral infections and antibiotic therapy. Otolaryngol Clin North Am 2011; 44: 57-78
19. Mitropoulos IF, Rotschafer JC, Rodvold KA. Adverse events associated with the use of oral cephalosporins/cephems. Diagn Microbiol Infect Dis 2007; 57: 67S-76S.
20. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008; 47: 735-43.
21. Rubinstein E, Labs R, Reeves A. A review of the adverse events profile of cefpirome. Drug Saf 1993; 9: 340-5.
22. Reinert RR. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect 2009; 15: 7-11.
23. McDermott PF, Walker RD, White DG. Antimicrobials: modes of action and mechanisms of resistance. Int J Toxicol 2003; 22: 135-43.
24. Levy SB. Antibiotic resistance: consequences of inaction. Clin Infect Dis 2001; 33: S124-9.
25. Jenkinson HF. Ins and outs of antimicrobial resistance: era of the drug pumps. J Dent Res 1996; 75: 736-42.
26. Neu HC. Current mechanisms of resistance to antimicrobial agents in microorganisms causing infection in the patient at risk for infection. Am J Med 1984; 76: 11-27.
27. Ellepola AN, Samaranayake LP. Oral candidal infections and antimycotics. Crit Rev Oral Biol Med 2000; 11: 172-98.
28. Hedderwick S, Kauffman CA. Opportunistic fungal infections: superficial and systemic candidiasis. Geriatrics 1997; 52: 50-54, 59.
29. Zegarelli DJ. Fungal infections of the oral cavity. Otolaryngol Clin North Am 1993; 26: 1069-89.
30. Li L, Redding S, Dongari-Bagtzoglou A. Candida glabrata: an emerging oral opportunistic pathogen. J Dent Res 2007; 86: 204-15.
31. Gouliouris T, Brown NM, Aliyu SH. Prevention and treatment of Clostridium difficile infection. Clin Med 2011; 11: 75-9.
32. Naves P, Del Prado G, Ponte C, Soriano F. Differences in the in vitro susceptibility of planktonic and biofilm-associated Escherichia coli strains to antimicrobial agents. J Chemother 2010; 22: 312-7.
33. Fey PD. Modality of bacterial growth presents unique targets: how do we treat biofilm-mediated infections? Curr Opin Microbiol 2010; 13: 610-5.
34. Lucchese G, Stufano A, Trost B, Kusalik A, Kanduc D. Peptidology: short amino acid modules in cell biology and immunology. Amino Acids 2007; 33: 703-7.
35. Kanduc D. Peptimmunology: immunogenic peptides and sequence redundancy. Curr Drug Discov Technol 2005; 2: 239-44.
36. Kanduc D. Defining peptide sequences: from antigenicity to immunogenicity through redundancy. Curr Pharmacogenomics 2006; 4: 33-7.
37. Willers J, Lucchese A, Kanduc D, Ferrone S. Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside. Peptides 1999; 20: 1021-6.
38. Natale C, Giannini T, Lucchese A, Kanduc D. Computer-assisted analysis of molecular mimicry between HPV16 E7 oncoprotein and human protein sequences. Immunol Cell Biol 2000; 78: 580-5.
39. Mittelman A, Lucchese A, Sinha AA, Kanduc D. Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome. Int J Cancer 2002; 98: 741-7.
40. Dummer R, Mittelman A, Fanizzi FP, Lucchese G, Willers J, Kanduc D. Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients. Int J Cancer 2004; 111: 720-6.
41. Kanduc D, Fanizzi FP, Lucchese G, Stevanovic S, Sinha AA, Mittelman A. NMR probing of in silico identification of anti-HPV16 E7 mAb linear peptide epitope. Peptides 2004; 25: 243-50.
42. Mittelman A, Tiwari R, Lucchese G, Willers J, Dummer R, Kanduc D. Identification of monoclonal anti-HMW-MAA antibody linear peptide epitope by proteomic database mining. J Invest Dermat 2004; 123: 670-5.
43. Willers J, Lucchese A, Mittelman A, Dummer R, Kanduc D. Definition of anti-tyrosinase MAb T311 linear determinant by proteome-based similarity analysis. Exp Dermatol 2005; 14: 543-50.
44. Lucchese A, Willers J, Mittelman A, Kanduc D, Dummer R. Proteomic scan for tyrosinase peptide antigenic pattern in vitiligo and melanoma. Role of sequence similarity and HLA-DR1 affinity. J Immunol 2005; 175: 7009-20.
45. Durr UHN, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 2006; 1758: 1408-25.
46. Cowland JB, Johnsen AH, Borregaard N. hCAP-18, a cathelin/probacternecin-like protein of human neutrophil specific granules. FEBS Lett 1995; 368: 173-6.
47. Larrick JW, Lee J, Ma S, Li X, Francke U, Wright SC et al. Structural, functional analysis and localization of human CAP18 gene. FEBS Lett 1996; 398: 74-80.
48. Okumura K. Cathelicidins-Therapeutic antimicrobial and antitumor host defense peptides for oral diseases. Jpn Dent Sci Rev 2011; 47: 67-81.
49. Nilsson-Frohm M, Sandstedt B, Sorenson O, Weber G, Borregaard N, Stahle-Backdahl M. The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is present in human squamous epithelia and colocalizes with interleukin-6. Infect Immun 1999; 67: 2561-6.
50. Murakami M, Dorschner RA, Gallo RL. Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J Dent Res 2002; 81: 845-52.
51. Devine DA. Antimicrobial peptides in defence of the oral and respiratory tracts. Mol Immunol 2003; 40: 431-43.
52. Isogai E, Isogai H, Matuo K, et al. Sensitivity of genera Porphyromonas and Prevotella to the bactericidal action of C-terminal domain of human CAP18 and its analogues. Oral Microbiol Immunol 2003; 18: 329-32.
53. Tanaka D, Miyasaki KT, Lehrer RI. Sensitivity of Actinobacillus actinomycetemcomitans and Capnocytophaga spp. to the bactericidal action of LL-37: a cathelicidin found in human leukocytes and epithelium. Oral Microbiol Immunol 2000; 15: 226-31.
54. Ouhara K, Komatsuzawa H, Yamada S, Shiba H, Fujiwara T, Ohara M, et al. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, {beta}-defensins and LL37, produced by human epithelial cells. J Antimicrob Chemother 2005; 55: 888-96.
55. Mookherjee N, Brown KL, Hancock REW. Cathelicidins: cationic host defense and antimicrobial peptides, In: Kastin, AJ. Ed., Handbook of Biologically Active Peptides. Elsevier Inc., 2006; 67-74.
56. Tjabringa GS, Aarbiou J, Ninaber DK, et al. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol 2003; 171: 6690-6.
57. Niyonsaba F, Iwabuchi K, Someya A, et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 2002; 106: 20-6.
58. Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur J Immunol 2001; 31: 1066-75.
59. Heilborn JD, Nilsson MF, Kratz G, et al. The cathelicidin antimicrobial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 2003; 120: 379-89.
60. Nagaoka I, Hirota S, Niyonsaba F, et al. Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells. J Immunol 2001; 167: 3329-38.
61. Nagaoka I, Hirota S, Niyonsaba F, et al. Augmentation of the lipopolysaccharide-neutralizing activities of human cathelicidin CAP18/LL-37-derived antimicrobial peptides by replacement with hydrophobic and cationic amino acid residues. Clin Diagn Lab Immunol 2002; 9: 972-82.
62. Tsukioka Y, Yamashita Y, Oho T, Nakano Y, Koga TD. Biological function of the dTDP-rhamnose synthesis pathway in Streptococcus mutans. J Bacteriol 1997; 179: 1126-34.
63. Tung-Yiu W, Jehn-Shyun H, Ching-Hung C, Hung-An C. Cervical necrotizing fasciitis of odontogenic origin: a report of 11 cases. J Oral Maxillofac Surg 2000; 58: 1347-52.
64. Henderson B, Poole S, Wilson M. Microbial/host interactions in health and disease: who controls the cytokine network? Immunopharmacology 1996; 35: 1-21.
65. Abiko Y, Nishimura M, Kaku T. Defensins in saliva and the salivary glands. Med Electron Microsc 2003; 36: 247-52.
66. Tao R, Jurevic RJ, Coulton KK, Tsutsui MT, Roberts MC, Kimball JR, et al. Salivary antimicrobial peptide expression and dental caries experience in children. Antimicrob Agents Chemother 2005; 49: 3883-8.
67. Dale BA, Tao R, Kimball JR, Jurevic RJ. Oral antimicrobial peptides and biological control of caries. BMC Oral Health 2006; 6: S13.
68. Dunsche A, Açil Y, Dommisch H, Siebert R, Schroder JM, Jepsen S. The novel human beta-defensin-3 is widely expressed in oral tissues. Eur J Oral Sci 2002; 110: 121-4.
69. Saygun I, Nizam N, Keskiner I, et al. Salivary infectious agents and periodontal disease status. J Periodontal Res 2011; 46: 235-9.
70. Yoo SY, Park SJ, Jeong DK, et al. Isolation and characterization of the mutans streptococci from the dental plaques in Koreans. J Microbiol 2007; 45: 246-55.
71. Ge Y, Caufield PW, Fisch GS, Li Y. Streptococcus mutans and Streptococcus sanguinis colonization correlated with caries experience in children. Caries Res 2008; 42: 444-8.
72. Yashin B, Pang M, Turner JS, et al. Evaluation of the inactivation of infectious Herpes simplex virus by host-defense peptides. Eur J Clin Microbiol Infect Dis 2000; 19: 187-94.
73. Weinberg A, Quiñones-Mateu ME, Lederman MM. Role of human beta-defensins in HIV infection. Adv Dent Res 2006; 19: 42-8.
74. Buck CB, Day PM, Thompson CD, et al. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci USA 2006; 103: 1516-21.
75. Feller L, Wood NH, Khammissa RA, Lemmer J. Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 1: human papillomavirus-mediated carcinogenesis. Head Face Med 2010; 6: 14.
76. Feller L, Wood NH, Khammissa RA, Lemmer J. Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 2: Human papillomavirus associated oral and oropharyngeal squamous cell carcinoma. Head Face Med 2010; 6: 15.
77. Popovi B, Jeki B, Novakovi I, et al. Cancer genes alterations and HPV infection in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2010; 39: 909-15.
78. Lucchese A, Serpico R, Guida A, Crincoli V, Scully C, Kanduc D. Interkeratin peptide-protein interactions that promote HPV16 E7 gene expression. Int J Immunopathol Pharmacol 2010; 23: 857-64.
79. Lucchese A, Serpico R. Effect of SP3 silencing on cytokeratin expression pattern in HPV-positive cells. Int J Immunopathol Pharmacol 2009; 22: 163-8.
80. Favia G, Kanduc D, Lo Muzio L, Lucchese A, Serpico R. Possible association between HPV16 E7 protein level and cytokeratin 19. Int J Cancer 2004; 111: 795-7.
81. Zushi Y, Narisawa-Saito M, Noguchi K, et al. An in vitro multistep carcinogenesis model for both HPV-positive and -negative human oral squamous cell carcinomas. Am J Cancer Res 2011; 1: 869-81.
82. Diamond G, Ryan L. Beta-defensins: what are they REALLY doing in the oral cavity? Oral Dis 2011; 17: 628-35.
83. Joly S, Compton LM, Pujol C, Kurago ZB, Guthmiller JM. Loss of human beta-defensin 1, 2, and 3 expression in oral squamous cell carcinoma. Oral Microbiol Immunol 2009; 24: 353-60.
84. Meyer JE, Harder J. Antimicrobial peptides in oral cancer. Curr Pharm Des 2007; 13: 3119-30.
85. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192: 553-60.
86. Kataoka Y, Miyazaki S, Yasuda S, et al. The first clinical pilot study of intravenous adrenomedullin administration in patients with acute myocardial infarction. J Cardiovasc Pharmacol 2010; 56: 413-9.
87. Deville JL, Salas S, Figarella-Branger D, Ouafik L, Daniel L. Adrenomedullin as a therapeutic target in angiogenesis. Expert Opin Ther Targets 2010; 14: 1059-72.
88. Shah KG, Rajan D, Jacob A, et al. Attenuation of renal ischemia and reperfusion injury by human adrenomedullin and its binding protein. J Surg Res 2010; 163: 110-7.
89. Chiu PC, Liao S, Lam KK, et al. Adrenomedullin regulates sperm motility and oviductal ciliary beat via cyclic adenosine 5'- monophosphate/protein kinase A and nitric oxide. Endocrinology 2010; 151: 3336-47.
90. Musson DS, McLachlan JL, Sloan AJ, Smith AJ, Cooper PR. Adrenomedullin is expressed during rodent dental tissue development and promotes cell growth and mineralization. Biol Cell 2010; 102: 145-57.
91. Tomson PL, Grover LM, Lumley PJ, Sloan AJ, Smith AJ, Cooper PR. Dissolution of bio-active dentine matrix components by mineral trioxide aggregate. J Dent 2007; 35: 636-42.
92. Hosokawa I, Hosokawa Y, Ozaki K, Nakae H, Matsuo T. Adrenomedullin suppresses tumour necrosis factor alpha-induced CXC chemokine ligand 10 production by human gingival fibroblasts. Clin Exp Immunol 2008; 152: 568-75.
93. Kapas S, Bansal A, Bhargava V, et al. Adrenomedullin expression in pathogen-challenged oral epithelial cells. Peptides 2001; 22: 1485-9.
94. Allaker RP, Kapas S. Adrenomedullin and mucosal defence: interaction between host and microorganism. Regul Pept 2003; 112: 147-52.
95. Tsai H, Bobek LA. Human Salivary histatins: promising antifungal therapeutic agents. Crit Rev Oral Biol Med 1998; 9: 480-97.
96. Sugiyama K, Ogino T, Ogata K. Rapid purification and characterization of histatins (histidine-rich polypeptides) from human whole saliva. Arch Oral Biol 1990; 35: 415-9.
97. Oppenheim FG, Xu T, McMillian FM, et al. Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol Chem 1988; 263: 7472-7.
98. Castagnola M, Inzitari R, Rossetti DV, et al. A cascade of 24 histatins (histatin 3 fragments) in human saliva. Suggestions for a pre-secretory sequential cleavage pathway. J Biol Chem 2004; 279: 41436-43.
99. MacKay BJ, Denepitiya L, Iacono VJ, Krost SB, Pollock JJ. Growth-inhibitory and bactericidal effects of human parotid salivary histidine-rich polypeptides on Streptococcus mutans. Infect Immun 1984; 44: 695-701.
100. Lupi A, Schininà ME, Denotti G, et al. Human salivary peptides derived from histatins. Eur J Morphol 2003; 41: 99-102.
101. Gusman H, Travis J, Helmerhorst EJ, Potempa J, Troxler RF, Oppenheim FG. Salivary histatin 5 is an inhibitor of both host and bacterial enzymes implicated in periodontal disease. Infect Immun 2001; 69: 1402-8.
102. Tsai H, Raj PA, Bobek LA. Candidacidal activity of recombinant human salivary histatin-5 and variants. Infect Immun 1996; 64: 5000-7.
103. Tsai H., Bobek LA. Human salivary histatin-5 exerts potent fungicidal activity against Cryptococcus neoformans. Biochim Biophys Acta 1997; 1336: 367-9.
104. Mickels N, McManus C, Massaro J, et al. Clinical and microbial evaluation of a histatin containing mouthrinse in humans with experimental gingivitis. J Clin Periodontol 2001; 28: 404-10.
105. Rothstein DM, Spacciapoli P, Tran LT, et al. Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5. Antimicrob Agents Chemother 2001; 45: 1367-73.
106. Yoshida M, Kimura T, Kitaichi K, et al. Induction of histamine release from rat peritoneal mast cells by histatins. Biol Pharm Bull 2001; 24: 1267-70.
107. Selivanova G, Ryabchenko L, Jansson E, Iotsova V, Wiman KG. Reactivation of Mutant p53 through Interaction of a C-terminal peptide with the core domain. Mol Cel Biol 1999; 19: 3395-402.
108. Baltaziak M, Duraj E, Koda M, et al. Expression of Bcl-xL, Bax, and p53 in primary tumors and lymph node metastases in oral squamous cell carcinoma. Ann N Y Acad Sci. 2006; 1090:18-25.
109. Chen SF, Yu FS, Chang YC, Fu E, Nieh S, Lin YS. Role of human papillomavirus infection in carcinogenesis of oral squamous cell carcinoma with evidences of prognostic association. J Oral Pathol Med Forthcoming 2011; doi: 10.1111/j.1600-0714.2011.01046.x.
110. Kato K, Kawashiri S, Yoshizawa K, et al. Expression form of p53 and PCNA at the invasive front in oral squamous cell carcinoma: correlation with clinicopathological features and prognosis. J Oral Pathol Med Forthcoming 2011; doi: 10.1111/j.1600-0714.2011.01032.x.
111. Zehbe I, Ciccolini F, Dell'Orco M, et al. E7 protein of human papillomaviruses and its interaction with cellular pathways, In P. Bannasch, D. Kanduc, S. Papa, and J. M. Tager Ed., Cell growth and oncogenesis. Birkhäuser Verlag, Basel, Switzerland. 1998; 97-107.
112. Acay R, Rezende N, Fontes A, Aburad A, Nunes F, Sousa S. Human papillomavirus as a risk factor in oral carcinogenesis: a study using in situ hybridization with signal amplification. Oral Microbiol Immunol 2008; 23: 271-4.
113. Kanduc D. Translational regulation of human papillomavirus type 16 E7 mRNA by the peptide SEQIKA, shared by rabbit alpha(1)- globin and human cytokeratin 7. J Virol 2002; 76: 7040-8.
114. Borja-Hart NL, Benavides S, Christensen C. Human papillomavirus vaccine safety in pediatric patients: an evaluation of the Vaccine Adverse Event Reporting. Ann Pharmacother 2009; 43: 356-9.
115. Eggertson L. Adverse events reported for HPV vaccine. CMAJ 2007; 177: 1169-70.
116. Kanduc D. Quantifying the possible cross-reactivity risk of an HPV16 vaccine. J Exp Ther Oncol 2009; 8: 65-76.
117. Crawford NW, Clothier HJ, Elia S, Lazzaro T, Royle J, Buttery JP. Syncope and seizures following human papillomavirus vaccination: a retrospective case series. Med J Aust 2011; 194: 16-8.
118. Johnsborg O, Eldholm V, Bjørnstad ML, Håvarstein LS. A predatory mechanism dramatically increases the efficiency of lateral gene transfer in Streptococcus pneumoniae and related commensal species. Mol Microbiol 2008; 69: 245-53.
119. Qi F, Kreth J, Lévesque CM, Kay O, et al. Peptide pheromone induced cell death of Streptococcus mutans. FEMS Microbiol Lett 2005; 251: 321-6.
120. Eckert R, He J, Yarbrough DK, Qi F, Anderson MH, Shi W. Targeted killing of Streptococcus mutans by a pheromone-guided smart antimicrobial peptide. Antimicrob Agents Chemother 2006; 50: 3651-7.
121. Kamarajan P, Garcia-Pardo A, D'Silva NJ, Kapila YL. The CS1 segment of fibronectin is involved in human OSCC pathogenesis by mediating OSCC cell spreading, migration, and invasion. BMC Cancer 2010; 10: 330.
122. Hsiao JR, Chang Y, Chen YL, et al. Cyclic alphavbeta6-targeting peptide selected from biopanning with clinical potential for head and neck squamous cell carcinoma. Head Neck 2001; 32: 160-72.
123. Kapoor V, Singh AK, Dey S, Sharma SC, Das SN. Circulating cycloxygenase-2 in patients with tobacco-related intraoral squamous cell carcinoma and evaluation of its peptide inhibitors as potential antitumor agent. J Cancer Res Clin Oncol 2001; 136: 1795-804.
124. Hong FD, Clayman GL. Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. Cancer Res 2000; 60: 6551-6.
125. Kawai N, Asaumi J, Murakami J, et al. Novel cell-surface peptides specific to human oral squamous cell carcinoma using an E. coli peptide display library. Oncol Rep 2007; 17: 787-91.
126. Angelini G, Bonamonte D, Lucchese A, et al. Preliminary data on Pemphigus vulgaris treatment by a proteomics-defined peptide: a case report. J Transl Med 2006; 4: 43.
127. Lucchese A, Mittelman A, Tessitore L, Serpico R, Sinha AA, Kanduc D. Proteomic definition of a desmoglein linear determinant common to Pemphigus vulgaris and Pemphigus foliaceous. J Transl Med 2006; 4: 37.
128. Angelini G, Bonamonte D, Lin MS, et al. Characterization of polyclonal antibodies raised against a linear peptide determinant of desmoglein-3. J Exp Ther Oncol 2005; 5: 1-7.
129. Lucchese A, Mittelman A, Lin MS, Kanduc D, Sinha AA. Epitope definition by proteomic similarity analysis: identification of the linear determinant of the anti-Dsg3 MAb 5H10. J Transl Med 2004; 2: 43.